

Response to erroneous media article

Sydney, Australia, Friday, 1 November 2019: Next Science Limited (ASX:NXS) (**Next Science/Company**), a pioneer biotechnology company, with multiple applications for commercialisation of its proprietary Xbio™ technology platform in the treatment of biofilm based infections (one of the leading causes of anti-microbial resistance), notes that it has been brought to its attention that an erroneous article regarding Next Science has been posted by Motley Fool on the Yahoo Finance website. The article significantly overstates the net cash used in operating activities for the year to date (9 months).

The Appendix 4C released by Next Science on Wednesday, 30 October 2019 did not contain any errors and net cash used in operating activities for the year to date (9 months) was as stated in that Appendix 4C.

Next Science confirms that it is in compliance with the ASX Listing Rules, in particular, Listing Rule 3.1 and that it will continue to keep shareholders fully informed in accordance with its continuous disclosure obligations.

For further information, please contact:

Judith Mitchell, Managing Director
Phone: +61 2 8607 5124
Email: investorqueries@nextscience.com

Michael Brown
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.

For further information visit: www.nextscience.com.